SGLT2 inhibitors, Now Part of the Cardiology Toolkit for Comprehensive CV Risk Management

Introduction/Background

T2DM as a Risk Factor for CVD

Close Linkage Between T2DM and HF

Intensive Glycemic Control Increased All-Cause Mortality (ACCORD)[a]

December 2008 FDA Guidance on Evaluating CV Risk in New Antidiabetic Therapies for T2DM

Assessing CV Risk in Antihyperglycemic Agents: Too Broad-Brush?

SAVOR-TIMI 53 (Saxagliptin): Hospitalization for HF

EXAMINE (Alogliptin): Hospitalization for HF[a,b]

TECOS (Sitagliptin): Hospitalization for HF

CV Safety Trials for the Gliptins: What Was the Point?

ELIXA (Lixisenatide): Primary Outcome CV Death, Nonfatal MI, Nonfatal Stroke, or Hospitalization for UA

LEADER: Primary Outcome Liraglutide vs Placebo*

Semaglutide Results: Renal Protection

Empagliflozin Modulates Several Factors Related to CV Risk

EMPA-REG OUTCOME: Trial Design

EMPA-REG Primary Outcome (3-Point MACE): CV Death, Nonfatal MI, or Nonfatal Stroke

EMPA-REG: Results for CV Death

EMPA-REG: Hospitalization for HF

EMPA-REG Microvascular Outcomes: Renal Protection

Kidney Damage and SGLT2 Inhibitors

EMPA-REG OUTCOME: Baseline Characteristics—CV Complications

Don't Ignore HF in T2DM

Potential Mechanisms for CV Benefit Associated With Empagliflozin

Is There a Role for SGLT2 Inhibitors in Patients Without T2DM?

Are EMPA-REG Data Changing Practice Patterns?

EMPA-REG Outcomes: Class Effect or Agent-Specific?

What Explains the Macro- and Microvascular Improvements Observed in LEADER?

Summary and Conclusions

Abbreviations

Abbreviations (cont)